Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37401
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN BROECKHOVEN, Jana-
dc.contributor.authorERENS, Celine-
dc.contributor.authorSOMMER, Daniela-
dc.contributor.authorSCHEIJEN, Elle-
dc.contributor.authorSANCHEZ, Selien-
dc.contributor.authorVidal, Pia M.-
dc.contributor.authorDOOLEY, Dearbhaile-
dc.contributor.authorVAN BREEDAM , Elise-
dc.contributor.authorQuarta, Alessandra-
dc.contributor.authorPONSAERTS, Peter-
dc.contributor.authorHENDRIX, Sven-
dc.contributor.authorLEMMENS, Stefanie-
dc.date.accessioned2022-06-02T07:33:16Z-
dc.date.available2022-06-02T07:33:16Z-
dc.date.issued2022-
dc.date.submitted2022-05-17T08:29:45Z-
dc.identifier.citationJournal of neuroinflammation, 19 (1) (Art N° 102)-
dc.identifier.urihttp://hdl.handle.net/1942/37401-
dc.description.abstractBackground Spinal cord injury (SCI) elicits a robust neuroinflammatory reaction which, in turn, exacerbates the initial mechanical damage. Pivotal players orchestrating this response are macrophages (M phi s) and microglia. After SCI, the inflammatory environment is dominated by pro-inflammatory M phi s/microglia, which contribute to secondary cell death and prevent regeneration. Therefore, reprogramming M phi/microglia towards a more anti-inflammatory and potentially neuroprotective phenotype has gained substantial therapeutic interest in recent years. Interleukin-13 (IL-13) is a potent inducer of such an anti-inflammatory phenotype. In this study, we used genetically modified M phi s as carriers to continuously secrete IL-13 (IL-13 M phi s) at the lesion site. Methods M phi s were genetically modified to secrete IL-13 (IL-13 M phi s) and were phenotypically characterized using qPCR, western blot, and ELISA. To analyze the therapeutic potential, the IL-13 M phi s were intraspinally injected at the perilesional area after hemisection SCI in female mice. Functional recovery and histopathological improvements were evaluated using the Basso Mouse Scale score and immunohistochemistry. Neuroprotective effects of IL-13 were investigated using different cell viability assays in murine and human neuroblastoma cell lines, human neurospheroids, as well as murine organotypic brain slice cultures. Results In contrast to M phi s prestimulated with recombinant IL-13, perilesional transplantation of IL-13 M phi s promoted functional recovery following SCI in mice. This improvement was accompanied by reduced lesion size and demyelinated area. The local anti-inflammatory shift induced by IL-13 M phi s resulted in reduced neuronal death and fewer contacts between dystrophic axons and M phi s/microglia, suggesting suppression of axonal dieback. Using IL-4R alpha-deficient mice, we show that IL-13 signaling is required for these beneficial effects. Whereas direct neuroprotective effects of IL-13 on murine and human neuroblastoma cell lines or human neurospheroid cultures were absent, IL-13 rescued murine organotypic brain slices from cell death, probably by indirectly modulating the M phi/microglia responses. Conclusions Collectively, our data suggest that the IL-13-induced anti-inflammatory M phi/microglia phenotype can preserve neuronal tissue and ameliorate axonal dieback, thereby promoting recovery after SCI.-
dc.description.sponsorshipThis study was supported by grants from Fund for Scientifc Research Flanders (FWO-Vlaanderen) to SH (G067715N, G091518N, G0C2120N). We also acknowledge partial funding from the University of Antwerp IOF-SBO brain organoid project and TRACER transgenic mouse project (both granted to PP) and the Belgian Charcot Foundation IL13 immunomodulation project (granted to PP). The authors would like to thank Dr. Leen Timmermans for her excellent technical assistance and Dr. Evi Lemmens for helping in the early phase of the research. In addition, we thank prof. Brône for providing CX3CR1/GFP mice, which were obtained from the European Mouse Mutant Archive (EMMA) with the approval of Jung et al. [60].-
dc.language.isoen-
dc.publisherBMC-
dc.rightsThe Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.-
dc.subject.otherCNS trauma-
dc.subject.otherNeuroinflammation-
dc.subject.otherMacrophages-
dc.subject.otherImmunomodulation-
dc.subject.otherInterleukin-13-
dc.subject.otherNeurospheroids-
dc.titleMacrophage-based delivery of interleukin-13 improves functional and histopathological outcomes following spinal cord injury-
dc.typeJournal Contribution-
dc.identifier.issue1-
dc.identifier.volume19-
local.format.pages19-
local.bibliographicCitation.jcatA1-
dc.description.notesHendrix, S (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, B-3590 Diepenbeek, Belgium.; Hendrix, S (corresponding author), Med Sch Hamburg, Kaiserkai 1, D-20457 Hamburg, Germany.-
dc.description.notessven.hendrix@medicalschool-hamburg.de-
local.publisher.placeCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr102-
dc.identifier.doi10.1186/s12974-022-02458-2-
dc.identifier.pmid35488301-
dc.identifier.isiWOS:000788885500004-
dc.contributor.orcidErens, Celine/0000-0002-7199-2153; Van Broeckhoven,-
dc.contributor.orcidJana/0000-0002-2884-1763-
dc.identifier.eissn1742-2094-
local.provider.typewosris-
local.description.affiliation[Van Broeckhoven, Jana; Erens, Celine; Sommer, Daniela; Sanchez, Selien; Hendrix, Sven; Lemmens, Stefanie] Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, B-3590 Diepenbeek, Belgium.-
local.description.affiliation[Scheijen, Elle] Hasselt Univ, Biomed Res Inst, Dept Neurosci, B-3590 Diepenbeek, Belgium.-
local.description.affiliation[Vidal, Pia M.] Univ Catolica Santisima Concepcion, Fac Med, Basic Sci Dept,Biomed Sci Res Lab, Neuroimmunol & Regenerat Cent Nervous Syst Unit, Concepcion 4090541, Chile.-
local.description.affiliation[Dooley, Dearbhaile] Univ Coll Dublin, Hlth Sci Ctr, Sch Med, Dublin 4, Ireland.-
local.description.affiliation[Dooley, Dearbhaile] Nivers Coll Dublin, UCD Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.-
local.description.affiliation[Van Breedam, Elise; Quarta, Alessandra; Ponsaerts, Peter] Univ Antwerp, Lab Expt Hematol, B-2610 Antwerp, Belgium.-
local.description.affiliation[Van Breedam, Elise; Quarta, Alessandra; Ponsaerts, Peter] Univ Antwerp, Vaccine & Infect Dis Inst Vaxinfectio, B-2610 Antwerp, Belgium.-
local.description.affiliation[Hendrix, Sven] Med Sch Hamburg, Kaiserkai 1, D-20457 Hamburg, Germany.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorVAN BROECKHOVEN, Jana-
item.contributorERENS, Celine-
item.contributorSOMMER, Daniela-
item.contributorSCHEIJEN, Elle-
item.contributorSANCHEZ, Selien-
item.contributorVidal, Pia M.-
item.contributorDOOLEY, Dearbhaile-
item.contributorVAN BREEDAM , Elise-
item.contributorQuarta, Alessandra-
item.contributorPONSAERTS, Peter-
item.contributorHENDRIX, Sven-
item.contributorLEMMENS, Stefanie-
item.fullcitationVAN BROECKHOVEN, Jana; ERENS, Celine; SOMMER, Daniela; SCHEIJEN, Elle; SANCHEZ, Selien; Vidal, Pia M.; DOOLEY, Dearbhaile; VAN BREEDAM , Elise; Quarta, Alessandra; PONSAERTS, Peter; HENDRIX, Sven & LEMMENS, Stefanie (2022) Macrophage-based delivery of interleukin-13 improves functional and histopathological outcomes following spinal cord injury. In: Journal of neuroinflammation, 19 (1) (Art N° 102).-
item.accessRightsOpen Access-
item.validationecoom 2023-
crisitem.journal.eissn1742-2094-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.